TITLE

Clinical pharmacokinetics: brief reports

PUB. DATE
April 2006
SOURCE
Drugs & Therapy Perspectives;Apr2006, Vol. 22 Issue 4, p16
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Advances in treatment for type 2 diabetes mellitus have seen an increase in polypharmacy. A higher incidence of hypoglycaemia may occur when multiple antihyperglycaemic agents are used. Potential interactions between oral glucose-lowering agents and other drugs (e.g. those that are widely coadministered in diabetic patients, have a narrow efficacy/toxicity ratio or are known to induce or inhibit the cytochrome P450 system) may have important clinical implications. As metformin is not metabolised and does not inhibit the metabolism of other drugs, there are no clinically relevant metabolic interactions with this agent. However, sulphonylureas, meglitinide derivatives and thiazolidinediones are extensively metabolised in the liver and may be subject to drug-drug metabolic interactions, resulting in either hypoglycaemia or worsening of metabolic control
ACCESSION #
20254476

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics